P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK

• Ivan Spicka,
• Ido Lapidot,
• Maximilian Merz,
• Jakub Radocha,
• Martin Stork,
• Tomas Jelínek,
• Alexandra Jungova,
• Jiri Minarik,
• Jan Soukup,
• Michel Van Speybroeck,
• Nolen Perualila,
• Joris Diels,
• João Duarte Mendes,
• Kirsten van Nimwegen,
• Kai Strobel,
• Sebastien Wischlen,
• Henrik Sliwka,
• Blanca Gros Otero,
• Roman Hajek

Affiliations

Ivan Spicka

1 1st Medical Department – Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic

Ido Lapidot

2 J-C Health Care Ltd., Kibbutz Shefayim, Israel

Maximilian Merz

3 Cell Therapy and Hemostaseology, Department of Hematology, University Hospital of Leipzig, Leipzig, Germany

Jakub Radocha

4 4th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic

Martin Stork

5 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic

Tomas Jelínek

6 Department of Haematooncology, University Hospital Ostrava and Department of Haematooncology, Faculty of Medicine University of Ostrava, Ostrava, Czech Republic

Alexandra Jungova

7 Hematology and Oncology Department, Charles University Hospital in Pilsen, Pilsen, Czech Republic

Jiri Minarik

8 Department of Hematooncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic

Jan Soukup

9 Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic

Michel Van Speybroeck

10 Janssen Pharmaceutica NV, Beerse, Belgium

Nolen Perualila

10 Janssen Pharmaceutica NV, Beerse, Belgium

Joris Diels

10 Janssen Pharmaceutica NV, Beerse, Belgium

João Duarte Mendes

11 Janssen Cilag, Porto Salvo, Portugal

Kirsten van Nimwegen

12 Janssen-Cilag B.V, Breda, the Netherlands, Breda, The Netherlands

Kai Strobel

13 TriNetX Oncology GmbH, Freiburg, Germany

Sebastien Wischlen

14 CancerDataNet GmbH, Basel, Czech Republic

Henrik Sliwka

15 Janssen-Cilag Pharma GmbH, Vienna, Austria

Blanca Gros Otero

16 Janssen-Cilag Spain, Madrid, Spain

Roman Hajek

17 University Hospital Ostrava, Department of Haematooncology, Ostrava, Czech Republic